| Rajay Kumar Jain, MD | |
|
1350 S Kings Dr, Charlotte, NC 28207-2134 | |
| (704) 446-4490 | |
| Not Available |
| Full Name | Rajay Kumar Jain |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 37 Years |
| Location | 1350 S Kings Dr, Charlotte, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710905302 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 200400523 (North Carolina) | Secondary |
| 207R00000X | Internal Medicine | 200400523 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| High Point Regional Health System | High point, NC | Hospital |
| North Carolina Baptist Hospital | Winston-salem, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wake Forest University Health Sciences | 4486564952 | 1987 |
| Carolinas Medical Center | 4789597477 | 735 |
News Archive
A minimally invasive procedure to determine whether patients with drug-resistant epilepsy are candidates for brain surgery is safer, more efficient, and leads to better outcomes than the traditional method, according to new research by The University of Texas Health Science Center at Houston.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The global peripheral vascular devices market is forecast to increase from $4.3 billion in 2010 to $5.3 billion by 2017, according to a new report available on companiesandmarkets.com.
Chile and Uruguay emerged as model cases last year for their handling of the COVID-19 crisis and are among the top five countriesin the world with the most vaccine doses administered per 100 people daily.
SAGE today announced they are launching a further three broad-spectrum open access journals - SAGE Open Medicine, SAGE Open Medical Case Reports and SAGE Open Engineering.
› Verified 3 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
A minimally invasive procedure to determine whether patients with drug-resistant epilepsy are candidates for brain surgery is safer, more efficient, and leads to better outcomes than the traditional method, according to new research by The University of Texas Health Science Center at Houston.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The global peripheral vascular devices market is forecast to increase from $4.3 billion in 2010 to $5.3 billion by 2017, according to a new report available on companiesandmarkets.com.
Chile and Uruguay emerged as model cases last year for their handling of the COVID-19 crisis and are among the top five countriesin the world with the most vaccine doses administered per 100 people daily.
SAGE today announced they are launching a further three broad-spectrum open access journals - SAGE Open Medicine, SAGE Open Medical Case Reports and SAGE Open Engineering.
› Verified 3 days ago
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
A minimally invasive procedure to determine whether patients with drug-resistant epilepsy are candidates for brain surgery is safer, more efficient, and leads to better outcomes than the traditional method, according to new research by The University of Texas Health Science Center at Houston.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The global peripheral vascular devices market is forecast to increase from $4.3 billion in 2010 to $5.3 billion by 2017, according to a new report available on companiesandmarkets.com.
Chile and Uruguay emerged as model cases last year for their handling of the COVID-19 crisis and are among the top five countriesin the world with the most vaccine doses administered per 100 people daily.
SAGE today announced they are launching a further three broad-spectrum open access journals - SAGE Open Medicine, SAGE Open Medical Case Reports and SAGE Open Engineering.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rajay Kumar Jain, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Rajay Kumar Jain, MD 1350 S Kings Dr, Charlotte, NC 28207-2134 Ph: (704) 446-4490 |
News Archive
A minimally invasive procedure to determine whether patients with drug-resistant epilepsy are candidates for brain surgery is safer, more efficient, and leads to better outcomes than the traditional method, according to new research by The University of Texas Health Science Center at Houston.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
The global peripheral vascular devices market is forecast to increase from $4.3 billion in 2010 to $5.3 billion by 2017, according to a new report available on companiesandmarkets.com.
Chile and Uruguay emerged as model cases last year for their handling of the COVID-19 crisis and are among the top five countriesin the world with the most vaccine doses administered per 100 people daily.
SAGE today announced they are launching a further three broad-spectrum open access journals - SAGE Open Medicine, SAGE Open Medical Case Reports and SAGE Open Engineering.
› Verified 3 days ago
Dr. Anish Kaushik Vani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 125 Queens Rd Ste 200, Charlotte, NC 28204 Phone: 704-343-9800 Fax: 704-347-2011 | |
John Michael Fedor, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1237 Harding Pl, Ste 3100, Charlotte, NC 28204 Phone: 704-373-0212 | |
Dr. Michael Warren Smith, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6115 Park South Dr Ste 100, Charlotte, NC 28210 Phone: 704-554-8787 Fax: 704-554-8774 | |
William Lane Jr., MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-4490 | |
Dr. Alagusivakumari Rameshbabu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10648 Park Rd, Charlotte, NC 28210 Phone: 704-667-8050 | |
Shibin Thomas Jacob, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 E W T Harris Blvd, Bldg 5000 Suite #5101, Charlotte, NC 28262 Phone: 704-863-5847 | |
Oscar Sven Brann, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6060 Piedmont Row Dr S Fl 10, Charlotte, NC 28287 Phone: 704-489-3094 |